Press Releases
At Pack/Pharma Expo, DIR Technologies to Debut “Lite” Version of Thermal Image-driven Induction Seal Inspection Solution for Bottles
Viable for Non-Pharma Sectors such as Food and Cosmetics, New Simplified System Provides Induction Sealing Integrity Analysis for 100% of Bottles without Packaging Line Slowdown Haifa, Israel – At Pack/Pharma Expo Las Vegas September 28-30, DIR Technologies,...
Press Releases
Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League
Bristol-Myers Squibb Company (NYSE:BMY) announced that 14 abstracts on Orencia have been accepted for presentation at the 2015 annual meeting of the European League Against Rheumatism (EULAR), to be held June 10-13 in Rome, Italy. ...
Press Releases
Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from...
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that results from an interim analysis of its Phase III, randomized, open-label ELOQUENT-2 trial were published in the June 2 online edition of the New England Journal of Medicine. ...
Press Releases
Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 36th Annual Global Health Care Conference on Tuesday, June 9, 2015, in Rancho Palos Verdes, CA. Michael Giordano, senior vice president, Head of Development, Oncology, will answer questions about...
Press Releases
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab)+Yervoy (ipilimumab) regimen in patients with previously untreated advanced melanoma. ...
Press Releases
Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer. At one...
Press Releases
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results of a Phase III trial (CheckMate -067) evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen or Opdivo monotherapy vs. Yervoy monotherapy in patients with previously untreated advanced melanoma. Both...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read